{"id":65012,"date":"2026-06-16T15:47:17","date_gmt":"2026-06-16T06:47:17","guid":{"rendered":"https:\/\/japanir.jp\/en\/ir\/4599-20260616-01_wp_basic\/"},"modified":"2026-07-12T12:07:39","modified_gmt":"2026-07-12T03:07:39","slug":"4599-20260616-01_wp_basic","status":"publish","type":"ir_release","link":"https:\/\/japanir.jp\/en\/company\/company-4599\/ir\/4599-20260616-01_wp_basic\/","title":{"rendered":"Notice of Patent Registration (Russia) for Regen-Inducing Drug Redasemotide (HMGB1 Fragment Peptide) Indicated for Fatty Liver and Non-Alcoholic Steatohepatitis"},"content":{"rendered":"","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4599","jir_company_name":"Stemomer? (Note: Original Japanese company name is \u682a\u5f0f\u4f1a\u793e\u30b9\u30c6\u30e0\u30ea\u30e0. Official English name is StemRim Co., Ltd. If available, use StemRim Co., Ltd.)","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-06-16","jir_source_link":"[Placeholder]","jir_short_summary":"Ukraine? Note: Please provide accurate official English name and context. Translation attempted:\nA patent covering the use of redasemtide for fatty liver\/NASH is expected to be registered in Russia. Applicants are StemRim, Osaka University, and Niigata University. No impact on the full-year results for the fiscal year ending July 2026. Future expansion of applications is insured.","jir_summary":"### News Overview\nThis release notifies that a use patent for fatty liver and nonalcoholic steatohepatitis (NASH) treatment using regenerative medicine\u00ae-developed redasemtide may be registered in Russia. Applicants are StemRim, Osaka University, and Niigata University (National University Corporation Osaka University, National University Corporation Niigata University). Invention title: Drug for treatment of fatty liver and nonalcoholic steatohepatitis. Filing region: Russia. Application number: 2024111536. Publication registration number: To be determined. At present, there is no anticipated impact on the full-year results for the fiscal year ending July 2026.\n\n### Impact on Business & Strategy\nThe patent registration aims to broaden the scope of application for redasemtide, enhancing the potential for global expansion including the Russian market. The program is currently in development, driven by the urgent need for new treatments in the fatty liver\/NASH space. In the long term, market opportunities are expected from expanded drug indications, but the direct financial impact at this time is unknown.","jir_financial_highlights":"Revenue: Unknown","jir_category":"Other","jir_hashtags":"#StemRim, #Redasemtide, #RussiaPatent","jir_key_figures":"Application number: 2024111536\nRegistration (publication) number: To be determined\nFiling region: Russia","jir_meta_title":"\u3010StemRim Co., Ltd.\u3011Notice of Redasemtide Patent Registration in Russia | FY2026 June","jir_meta_description":"Redasemtide patent for fatty liver\/NASH in Russia is scheduled for registration. Applicants include StemRim and others; no direct impact on the FY2026 guidance. Summary of the latest notice.","jir_og_title":"\u3010StemRim Co., Ltd.\u3011Notice of Russia Patent Registration","jir_og_description":"Fatty liver\/NASH use patent for redasemtide is planned to be registered in Russia. Financial impact is currently unknown; attention to future market expansion.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58112,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-65012","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notice of Patent Registration (Russia) for Regen-Inducing Drug Redasemotide (HMGB1 Fragment Peptide) Indicated for Fatty Liver and Non-Alcoholic Steatohepatitis - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4599\/ir\/4599-20260616-01_wp_basic\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4599\/ir\/4599-20260616-01_wp_basic\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4599\/ir\/4599-20260616-01_wp_basic\/\",\"name\":\"Notice of Patent Registration (Russia) for Regen-Inducing Drug Redasemotide (HMGB1 Fragment Peptide) Indicated for Fatty Liver and Non-Alcoholic Steatohepatitis - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-06-16T06:47:17+00:00\",\"dateModified\":\"2026-07-12T03:07:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4599\/ir\/4599-20260616-01_wp_basic\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4599\/ir\/4599-20260616-01_wp_basic\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4599\/ir\/4599-20260616-01_wp_basic\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Notice of Patent Registration (Russia) for Regen-Inducing Drug Redasemotide (HMGB1 Fragment Peptide) Indicated for Fatty Liver and Non-Alcoholic Steatohepatitis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Notice of Patent Registration (Russia) for Regen-Inducing Drug Redasemotide (HMGB1 Fragment Peptide) Indicated for Fatty Liver and Non-Alcoholic Steatohepatitis - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4599\/ir\/4599-20260616-01_wp_basic\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4599\/ir\/4599-20260616-01_wp_basic\/","url":"https:\/\/japanir.jp\/en\/company\/company-4599\/ir\/4599-20260616-01_wp_basic\/","name":"Notice of Patent Registration (Russia) for Regen-Inducing Drug Redasemotide (HMGB1 Fragment Peptide) Indicated for Fatty Liver and Non-Alcoholic Steatohepatitis - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-06-16T06:47:17+00:00","dateModified":"2026-07-12T03:07:39+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4599\/ir\/4599-20260616-01_wp_basic\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4599\/ir\/4599-20260616-01_wp_basic\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4599\/ir\/4599-20260616-01_wp_basic\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"Notice of Patent Registration (Russia) for Regen-Inducing Drug Redasemotide (HMGB1 Fragment Peptide) Indicated for Fatty Liver and Non-Alcoholic Steatohepatitis"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"related_company_data":{"id":"58112","title":"(\u682a)\u30b9\u30c6\u30e0\u30ea\u30e0","ticker":"4599"},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/65012","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/ir_release"}],"replies":[{"embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/comments?post=65012"}],"version-history":[{"count":1,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/65012\/revisions"}],"predecessor-version":[{"id":79244,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/65012\/revisions\/79244"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=65012"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=65012"},{"taxonomy":"importance","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/importance?post=65012"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}